From Recall to Reinvention: Advita Ortho's Bet on Quality

GAINESVILLE, FL – January 26, 2026 – Global medical technology company Advita Ortho today launched “Quality in Action,” a comprehensive, company-wide initiative aimed at embedding a quality-first mindset into every facet of its business. The program seeks to formalize the company's commitment to excellence in a sector where product reliability is paramount.

In the official announcement, company leadership positioned the initiative as a foundational cultural shift. "Quality is not owned by a single department," said CEO Aurelio Sahagun. "It lives in how teams collaborate, how data is utilized and how we anticipate challenges before they arise. This initiative brings that philosophy to life in a way that is visible, measurable and sustainable."

The program is built on three core pillars: Shared Ownership, which empowers all employees to take responsibility for quality; Real-Time Intelligence, which leverages data and analytics for proactive decision-making; and Proactive Prevention, which focuses on early risk identification through rigorous testing and supplier collaboration.

"At its core, quality is about trust," added Christine Thomas, Chief Quality, Regulatory and Clinical Officer. "In our industry, surgeons and patients rely on us to deliver solutions that perform effectively and safely. Quality in Action formalizes our philosophy that, rather than being a checkpoint, quality is a mindset that must be actively practiced, measured and continuously improved."

While the announcement presents a forward-looking vision, it arrives in the long shadow of the company's predecessor, casting the initiative as both a strategic necessity and a crucial test of its ability to rebuild trust.

A Legacy of Recalls and a Quest for Trust

Advita Ortho is, for all practical purposes, a new name for a familiar entity. The company officially launched in November 2025 after emerging from the Chapter 11 bankruptcy and restructuring of Exactech, a firm whose name became synonymous with significant product failures. This history provides the critical context for the "Quality in Action" launch.

Between 2021 and 2023, Exactech faced a series of widespread Class II FDA recalls affecting thousands of its orthopedic implants. The issues stemmed from a critical manufacturing flaw: defective vacuum-seal bags that lacked a necessary oxygen barrier layer. This packaging failure allowed oxygen to permeate and oxidize the polyethylene components of hip liners, knee systems, and ankle implants, leading to premature wear, component fractures, and device failure. Patients experienced complications including bone loss, pain, and the need for costly and invasive revision surgeries.

The recalls impacted established product lines such as the Connexion GXL hip liners, Optetrak and Truliant knee systems, and Vantage ankle replacements. The fallout was immense, resulting in over 2,600 product liability claims and mounting litigation costs that ultimately pushed Exactech into bankruptcy.

Advita Ortho was born from the sale of Exactech's assets, now under the new leadership of CEO Aurelio Sahagun, who was not with the former company during its period of regulatory challenges. The new entity continues to market some of the same established product lines, including the Truliant Knee and Equinoxe Shoulder. This lineage makes the "Quality in Action" initiative less of a routine corporate program and more of a foundational statement of intent—an explicit effort to break from a troubled past and establish a new reputation grounded in reliability.

Deconstructing 'Quality in Action'

Advita Ortho's plan to rebuild its reputation rests on the practical implementation of its three pillars. The initiative appears designed to directly address the systemic failures that plagued its predecessor.

The first pillar, Shared Ownership, signals a move away from siloed quality control departments. By aiming to make every employee an agent of quality, the company is attempting a deep cultural overhaul. This is a direct response to a history where quality checks failed to prevent a catastrophic packaging flaw from affecting products for years. It reframes quality as a collective responsibility, from the C-suite to the manufacturing floor and out to the sales representatives partnering with surgeons.

Real-Time Intelligence leans into the modern medtech trend of data-driven operations. Advita Ortho states it specializes in surgical technologies powered by data, AI, and machine learning. This pillar promises to apply that same technological rigor internally, using analytics and live dashboards to monitor processes, detect anomalies, and enable faster, more informed decisions. For a company recovering from defects that went unnoticed for an extended period, the ability to gain real-time visibility into manufacturing and supply chain performance is critical.

Perhaps most directly, the Proactive Prevention pillar confronts the root cause of Exactech's downfall. The focus on identifying risks through rigorous testing and, crucially, supplier collaboration, is a clear lesson learned. Research into Advita's publicly available supplier documents, such as its "Quality Agreement," reveals strict new requirements. Suppliers are now mandated to maintain robust quality management systems, adhere to restricted substance policies, and provide detailed Certificates of Conformance for all components. Significantly, the agreement holds suppliers financially accountable for costs associated with recalls stemming from non-conforming deliverables—a clause that directly addresses the previous packaging failures.

Industry Scrutiny and the Shadow of 'Quality-Washing'

Despite the initiative's comprehensive framework, Advita Ortho faces a steep climb against industry and consumer skepticism. In a market where trust is the ultimate currency, the announcement will inevitably be scrutinized for signs of "quality-washing"—a public relations campaign designed to gloss over deep-seated issues without substantive change.

The central challenge lies in demonstrating that this transformation is genuine. Surgeons and hospital administrators who experienced the disruption of the Exactech recalls will be watching closely for tangible proof of improved product performance and post-market surveillance. The continuation of legacy product lines, such as the Truliant knee system which was previously involved in litigation, places an even greater burden on Advita to prove its new processes are effective.

The medical device industry operates under intense regulatory pressure from bodies like the FDA and its European counterparts. While Advita Ortho is a new legal entity, its operational history will not be forgotten. The company's success will depend on its ability to not only meet but exceed current quality standards, creating a track record of reliability that can slowly erase the memory of past failures.

As it moves forward with its new credit facility and recent innovation awards, the company's greatest test will not be in its press releases or on its website. It will be in the operating rooms and in the long-term outcomes of patients who receive its devices. For Advita Ortho, 'Quality in Action' cannot just be a slogan; it must be the demonstrable reality of its daily operations if it hopes to complete its journey from recall to reinvention.